Emergent BioSolutions (EBS) – Get Report shares rose Wednesday after the life sciences company and Mount Sinai Health System announced a trial for Emergent’s coronavirus preventative with $34.6 million of support from the Pentagon.
Emergent recently traded at $92.70, up 2.84%, and has surged 71% year to date amid investor enthusiasm for companies involved with Covid treatments.
{iframe}https://www.thestreet.com/investing/emergent-biosolutions-dod-aid-covid-treatment-test{/iframe}